Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
NEWARK, Calif., Feb. 03, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the following healthcare conferences during the month of February.
LEERINK Partners 5th Annual Global Healthcare Conference
Date: Wednesday, February 10, 2016
Time: 11:55 a.m. EST
Location: New York, New York
2016 RBC Capital Markets’ Global Healthcare Conference
Date: Wednesday, February 24, 2016
Time: 11:00 a.m. EST
Location: New York, New York
These presentations will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
